vs

Side-by-side financial comparison of Avidity Biosciences, Inc. (RNA) and SPAR Group, Inc. (SGRP). Click either name above to swap in a different company.

SPAR Group, Inc. is the larger business by last-quarter revenue ($22.0M vs $12.5M, roughly 1.8× Avidity Biosciences, Inc.). SPAR Group, Inc. runs the higher net margin — -74.1% vs -1398.3%, a 1324.2% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs -33.4%). SPAR Group, Inc. produced more free cash flow last quarter ($-3.9M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs -33.2%).

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

SPAR, originally "DESPAR", styled as "DE SPAR", is a Dutch multinational franchise that provides branding, supplies and support services for independently owned and operated food retail stores. It was founded in the Netherlands in 1932, by Adriaan van Well, although the largest number of stores are located in the United Kingdom.

RNA vs SGRP — Head-to-Head

Bigger by revenue
SGRP
SGRP
1.8× larger
SGRP
$22.0M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+467.4% gap
RNA
434.0%
-33.4%
SGRP
Higher net margin
SGRP
SGRP
1324.2% more per $
SGRP
-74.1%
-1398.3%
RNA
More free cash flow
SGRP
SGRP
$153.0M more FCF
SGRP
$-3.9M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
-33.2%
SGRP

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
RNA
RNA
SGRP
SGRP
Revenue
$12.5M
$22.0M
Net Profit
$-174.4M
$-16.3M
Gross Margin
-10.6%
Operating Margin
-1513.5%
-57.8%
Net Margin
-1398.3%
-74.1%
Revenue YoY
434.0%
-33.4%
Net Profit YoY
-117.0%
-186.2%
EPS (diluted)
$-1.27
$-0.69

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RNA
RNA
SGRP
SGRP
Q4 25
$22.0M
Q3 25
$12.5M
$41.4M
Q2 25
$3.8M
$38.6M
Q1 25
$1.6M
$34.0M
Q4 24
$3.0M
$33.0M
Q3 24
$2.3M
$37.8M
Q2 24
$2.0M
$43.4M
Q1 24
$3.5M
$49.4M
Net Profit
RNA
RNA
SGRP
SGRP
Q4 25
$-16.3M
Q3 25
$-174.4M
$-8.8M
Q2 25
$-157.3M
$-1.0K
Q1 25
$-115.8M
$462.0K
Q4 24
$-102.3M
$-5.7M
Q3 24
$-80.4M
$-182.0K
Q2 24
$-70.8M
$-3.9M
Q1 24
$-68.9M
$6.6M
Gross Margin
RNA
RNA
SGRP
SGRP
Q4 25
-10.6%
Q3 25
18.6%
Q2 25
23.5%
Q1 25
21.4%
Q4 24
19.6%
Q3 24
22.3%
Q2 24
20.7%
Q1 24
19.7%
Operating Margin
RNA
RNA
SGRP
SGRP
Q4 25
-57.8%
Q3 25
-1513.5%
-14.3%
Q2 25
-4448.7%
1.9%
Q1 25
-8360.9%
3.0%
Q4 24
-4069.6%
-16.6%
Q3 24
-4200.9%
-4.0%
Q2 24
-4040.4%
-2.2%
Q1 24
-2178.6%
17.6%
Net Margin
RNA
RNA
SGRP
SGRP
Q4 25
-74.1%
Q3 25
-1398.3%
-21.2%
Q2 25
-4089.3%
-0.0%
Q1 25
-7360.0%
1.4%
Q4 24
-3439.5%
-17.3%
Q3 24
-3441.7%
-0.5%
Q2 24
-3461.8%
-9.0%
Q1 24
-1943.4%
13.4%
EPS (diluted)
RNA
RNA
SGRP
SGRP
Q4 25
$-0.69
Q3 25
$-1.27
$-0.37
Q2 25
$-1.21
$0.00
Q1 25
$-0.90
$0.02
Q4 24
$-0.80
$-0.24
Q3 24
$-0.65
$-0.01
Q2 24
$-0.65
$-0.16
Q1 24
$-0.79
$0.28

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RNA
RNA
SGRP
SGRP
Cash + ST InvestmentsLiquidity on hand
$350.2M
$3.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.9B
$622.0K
Total Assets
$2.1B
$44.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RNA
RNA
SGRP
SGRP
Q4 25
$3.3M
Q3 25
$350.2M
$8.2M
Q2 25
$243.9M
$13.9M
Q1 25
$254.2M
$17.9M
Q4 24
$219.9M
$18.2M
Q3 24
$370.2M
$19.7M
Q2 24
$575.8M
$21.7M
Q1 24
$471.4M
$16.6M
Stockholders' Equity
RNA
RNA
SGRP
SGRP
Q4 25
$622.0K
Q3 25
$1.9B
$16.6M
Q2 25
$1.2B
$24.9M
Q1 25
$1.3B
$24.7M
Q4 24
$1.4B
$24.3M
Q3 24
$1.5B
$29.3M
Q2 24
$1.2B
$29.4M
Q1 24
$830.9M
$33.0M
Total Assets
RNA
RNA
SGRP
SGRP
Q4 25
$44.1M
Q3 25
$2.1B
$61.7M
Q2 25
$1.4B
$71.6M
Q1 25
$1.5B
$70.2M
Q4 24
$1.6B
$56.4M
Q3 24
$1.6B
$67.4M
Q2 24
$1.3B
$70.0M
Q1 24
$951.5M
$104.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RNA
RNA
SGRP
SGRP
Operating Cash FlowLast quarter
$-156.2M
$-2.5M
Free Cash FlowOCF − Capex
$-156.9M
$-3.9M
FCF MarginFCF / Revenue
-1257.6%
-17.8%
Capex IntensityCapex / Revenue
5.7%
6.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-592.3M
$-21.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RNA
RNA
SGRP
SGRP
Q4 25
$-2.5M
Q3 25
$-156.2M
$-4.1M
Q2 25
$-199.7M
$-7.9M
Q1 25
$-124.8M
$-4.0M
Q4 24
$-99.9M
$65.0K
Q3 24
$-65.6M
$-900.0K
Q2 24
$-65.0M
$-445.0K
Q1 24
$-70.4M
$615.0K
Free Cash Flow
RNA
RNA
SGRP
SGRP
Q4 25
$-3.9M
Q3 25
$-156.9M
$-4.6M
Q2 25
$-203.0M
$-8.3M
Q1 25
$-128.6M
$-4.6M
Q4 24
$-103.8M
$-166.0K
Q3 24
$-67.3M
$-1.0M
Q2 24
$-65.5M
$-785.0K
Q1 24
$-71.3M
$184.0K
FCF Margin
RNA
RNA
SGRP
SGRP
Q4 25
-17.8%
Q3 25
-1257.6%
-11.2%
Q2 25
-5277.1%
-21.5%
Q1 25
-8174.3%
-13.4%
Q4 24
-3491.0%
-0.5%
Q3 24
-2881.8%
-2.7%
Q2 24
-3204.6%
-1.8%
Q1 24
-2012.3%
0.4%
Capex Intensity
RNA
RNA
SGRP
SGRP
Q4 25
6.6%
Q3 25
5.7%
1.4%
Q2 25
86.9%
1.1%
Q1 25
238.6%
1.5%
Q4 24
131.7%
0.7%
Q3 24
72.9%
0.3%
Q2 24
26.0%
0.8%
Q1 24
25.8%
0.9%
Cash Conversion
RNA
RNA
SGRP
SGRP
Q4 25
Q3 25
Q2 25
Q1 25
-8.75×
Q4 24
Q3 24
Q2 24
Q1 24
0.09×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons